Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
A phase III trial with a 2×2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial
What is the Definition of Misclassification in Patients with Grade Group 2 prostate cancer Eligible for Active Surveillance and diagnosed with MRI targeted biopsy? A multi-institutional analysis with pathological confirmation
Should we routinely recommend a central review of magnetic resonance imaging of the prostate in men with positive mp-MRI? Implication for targeted biopsies
Pembrolizumab (Pembro) Plus Olaparib in Patients With Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer (mCRPC): Updated Results From KEYNOTE-365 Cohort A With a Minimum of 11 Months of Follow-Up for All Patients